1. Home
  2. INDP vs SOR Comparison

INDP vs SOR Comparison

Compare INDP & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

N/A

Current Price

$3.18

Market Cap

438.4M

Sector

Health Care

ML Signal

N/A

Logo Source Capital Inc.

SOR

Source Capital Inc.

N/A

Current Price

$45.49

Market Cap

383.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
INDP
SOR
Founded
2000
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
438.4M
383.4M
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
INDP
SOR
Price
$3.18
$45.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 211.2K
6.8K
Earning Date
11-13-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$44.20
52 Week High
$5.96
$50.41

Technical Indicators

Market Signals
Indicator
INDP
SOR
Relative Strength Index (RSI) 50.79 41.12
Support Level $2.17 $44.89
Resistance Level $3.71 $47.25
Average True Range (ATR) 0.34 0.99
MACD -0.02 -0.18
Stochastic Oscillator 51.34 3.66

Price Performance

Historical Comparison
INDP
SOR

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About SOR Source Capital Inc.

Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.

Share on Social Networks: